Lung Cancer and Immunotherapy experience from second line and beyond

ABSTRACT

Introduction: Lung cancer represents the leading cause of cancer death worldwide. At diagnosis, the majority of patients present an advanced or metastatic disease. Despite the improvement in diagnostic and therapeutic strategies, lung cancer prognosis remains poor with less than 15 percent of patients surviving beyond 5 years. Advanced non-small-cell lung cancer [NSCLC] has been always treated by platinum-based regimens with various toxicity profiles However, with the discovery of the PD-1/PD-L1 pathway, novel checkpoint inhibitors emerged as promising agents for treating patients with advanced disease. When evaluated in clinical trials, they showed promising results and durable responses in a subset of patients treated in the first and second lines or beyond. The aim of this study is to assess the efficacy and responses of these agents in real-life practice when used in second line or after